StreetInsider.com News Articles

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

MELBOURNE, Australia, May 07, 2025 (GLOBE NEWSWIRE) -- CLINUVEL has met its recruitment target in its phase III trial (CUV105) of SCENESSE® (afamelanotide 16mg) in vitiligo, with more than 200 patients enrolled. The last patient to enter the study is scheduled to complete screening in May 2025. First results from the study are expected in the second half

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Wed, 07 May 2025 00:10:00 -0400

Executive summary

Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved
Randomised trial, 20-week treatment protocol plus 6-month follow up
Study sites in North America, Africa and Europe
First clinical observations with afamelanotide positive

Clinuvel Introduces Groundbreaking Vitiligo Program at the World’s Biggest Dermatology Meeting, AAD 2025

Mon, 03 Mar 2025 21:17:00 -0400

MELBOURNE, Australia, March 03, 2025 (GLOBE NEWSWIRE) -- World-leading photomedicine company CLINUVEL will make its début at the American Academy of Dermatology (AAD) Annual Meeting from March 7–11, with an immersive exhibition that illuminates the past, present and future of photomedicine.

The 4,800-square-foot Pavilion of Photomedicine has been custom built for CLINUVEL for the AAD Meeting to provide an immersive experience on the history, evolution, and future of photomedicine, including CLINUVEL’s development program with the novel drug SCENESSE® (afamelanotide) to treat vitiligo and work with other melanocortins.

Visitors will travel through five curated courts to experience

Clinuvel Introduces Groundbreaking Vitiligo Program at the World’s Biggest Dermatology Meeting, AAD 2025

Mon, 03 Mar 2025 21:17:00 -0400

Visitors will travel through five curated courts to experience

Clinuvel Introduces Groundbreaking Vitiligo Program at the World’s Biggest Dermatology Meeting, AAD 2025

Mon, 03 Mar 2025 21:17:00 -0400

Visitors will travel through five curated courts to experience